Fresenius Medical Care AG & Co. KGaA (FMS) Stock Analysis & Investment Frameworks
Fresenius Medical Care AG & Co. KGaA (FMS) stock analysis on Invetso. Review Fresenius Medical Care AG & Co. KGaA’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Fresenius Medical Care AG & Co. KGaA Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Medical - Care Facilities
- Country: DE
Fresenius Medical Care AG & Co. KGaA Key Financial Metrics
- Market Cap: $12.45B
- Revenue: $21.87B
- P/E Ratio: 11.41
- ROE: 6.34%
- ROIC: 6.05%
- Dividend Yield: 3.53%
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Fresenius Medical Care AG & Co. KGaA Investment Frameworks
Invetso analyzes Fresenius Medical Care AG & Co. KGaA (FMS) across the following frameworks:
- Fresenius Medical Care AG & Co. KGaA 10Y Growth Potential
- Fresenius Medical Care AG & Co. KGaA Scenario Analysis
- Fresenius Medical Care AG & Co. KGaA Risks & Opportunities
- Fresenius Medical Care AG & Co. KGaA Economic Moat
- Fresenius Medical Care AG & Co. KGaA Business Model
- Fresenius Medical Care AG & Co. KGaA Management
- Fresenius Medical Care AG & Co. KGaA SWOT Analysis
- Fresenius Medical Care AG & Co. KGaA Porter's 5 Forces
- Fresenius Medical Care AG & Co. KGaA PESTLE Analysis
- Fresenius Medical Care AG & Co. KGaA ESG Analysis